Pulmonary Hypertension

Cardiovascular·MeSH: Hypertension, Pulmonary

Prevalence

47000.0 / 100K

Incidence

3000.0 / 100K/yr

16 drugs in development·9 companies·24 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
tyvaso dpi	MANNKIND CORP (MNKD)
YUTREPIA	Liquidia Corp (LQDA)

Phase 3(5)

Drug	Company
Duo-Therapy with Sildenafil + Bosentan	Crinetics Pharmaceuticals, Inc. (CRNX)
Inhaled treprostinil	UNITED THERAPEUTICS Corp (UTHR)
L606	Liquidia Corp (LQDA)
Mono-Therapy with Sildenafil	Crinetics Pharmaceuticals, Inc. (CRNX)
tnx-103	TENAX THERAPEUTICS, INC. (TENX)

Phase 2(6)

Drug	Company
inopulse	Bellerophon Therapeutics, Inc. (BLPH)
mosliciguat	Roivant Sciences Ltd. (ROIV)
Mosliciguat	Crinetics Pharmaceuticals, Inc. (CRNX)
tx000045- dose a	Tectonic Therapeutic, Inc. (TECX)
tx000045- dose b	Tectonic Therapeutic, Inc. (TECX)
tx45	Tectonic Therapeutic, Inc. (TECX)

Phase 1(1)

Drug	Company
Treprostinil Palmitil	INSMED Inc (INSM)

Unknown(1)

Drug	Company
LIQ861	Liquidia Corp (LQDA)

Phase 4(1)

Drug	Company
inhaled treprostinil	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 16 drugs in development for Pulmonary Hypertension across 9 companies.

There are 24 clinical trials targeting Pulmonary Hypertension tracked by BioSniper.

The estimated prevalence of Pulmonary Hypertension is approximately 47000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.